Sino Biological, a leading recombinant protein producer, is pleased to announce the expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration combines Sino Biological’s advanced protein expression and wet lab capabilities with BioGeometry’s creative AI protein design and optimization platform. The two companies aim to strengthen their joint offerings and explore high-value market opportunities worldwide.
Sino Biological is committed to promoting innovation in biomanufacturing by incorporating cutting-edge technologies. The company’s expertise in protein and antibody research, combined with BioGeometry’s breakthroughs in genetic artificial intelligence, offers unparalleled solutions for protein design and optimization. This collaboration is set to significantly accelerate the pace of discovery for researchers and pharmaceutical companies, providing customers with access to faster, more efficient protein R&D services.
Image credit: Sino Biological
Deep learning, particularly large-scale generative artificial intelligence models, is revolutionizing biofabrication. AlphaFold3, using diffusion models, can now predict the structures of biomolecules, greatly advancing protein design. BioGeometry, a leader in genetic artificial intelligence for protein design, pioneered diffusion models with the influential 2021 “GeoDiff” paper. In June, BioGeometry introduced GeoFlow, a protein foundation model that excels in structure prediction and design, competing with AlphaFold3 in antigen-antibody complex prediction. Freely available for non-commercial use, GeoFlow is integrated into BioGeometry’s GeoBiologics platform, improving the efficiency of protein design with fewer experiments.
Sino Biological and BioGeometry’s collaboration to combine genetic artificial intelligence with liquid lab experiments offers advanced research tools and CRO services. Their collaboration leverages BioGeometry’s GeoFlow platform and Sino Biological’s protein expression capabilities to improve design efficiency and accuracy. By updating AI models with experimental data, they accelerate project completion. They have already successfully developed nanosomes and enzymes and aim to further innovate AI-driven protein research, contributing to advances in biopharmaceuticals, disease treatment and sustainable development.
Sino Biological has long been recognized for its comprehensive CRO technical service platform, which includes gene cloning, protein expression, antibody development and quality control research. With capabilities spanning from gene sequencing to large-scale production, Sino Biological provides preclinical production services with unparalleled speed, producing purified monoclonal antibodies in just a few weeks. The company’s vast library of proteins and antibodies, together with its extensive screening and manufacturing platforms, positions Sino Biological as a global leader in life science research and innovative drug development.
Looking ahead, Sino Biological and BioGeometry will continue to explore new applications of artificial intelligence in protein research and development, aiming to shape the future of biopharmaceutical R&D and make significant contributions to disease treatment and sustainable scientific progress.
